BioWorld Asia

Oct. 6, 2010

One GIANT Step for Mankind: New Genes for Height Control

Agennix Nets $105M in Share Offer to Develop Talactoferrin

GW Testing Cannabinoids in Diabetes, Metabolic Syndrome

'Father of 4 Million' Wins Medicine Nobel for IVF Work

Other News To Note

Zealand's Lixisenatide Hits Mark in Phase III Combo Trial

Lixisenatide, the Type II diabetes molecule discovered by Zealand Pharma A/S, met the primary endpoint in the first Phase III combination trial. (BioWorld International) Read More

GlaxoSmithKline Spins Out Firm with Ion Channel Portfolio

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Medline raises $6.3B in fourth med-tech IPO of December

BioWorld MedTech

Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

Vitesse finesse pays off: DBV wins in peanut allergy phase III

BioWorld

DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

Acryl raises $28M IPO, aiming to bridge medical divide with AI

BioWorld MedTech

Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...